Q1 2025 AxoGen Inc Earnings Call Transcript

May 8, 2025 / 12:00 PM GMT

Release Date Price: €14.4 (+0.70%)

Transcript 10-Q8-K

Key Points

Positve

Axogen Inc (AXGN) reported a 17.4% increase in revenue for the first quarter of 2025, reaching $48.6 million, driven by double-digit growth across all target markets.
The company successfully increased average account productivity by 24% in high potential accounts, surpassing their target of 21%.
Axogen Inc (AXGN) is on track with its biologics license application (BLA) for advanced nerve graft, expecting approval in September, which will secure 12 years of market exclusivity.
The company has made strategic hires across sales, marketing, and market access teams to strengthen its commercial infrastructure.
Axogen Inc (AXGN) continues to see strong external validation with eight new peer-reviewed publications citing clinical use or discussion of its products.

Negative

Gross margin decreased to 71.9% from 78.8% in the same period last year, impacted by higher costs at the new facility and increased inventory reserves.
The company is running behind its original hiring and training plan for expanding the breast re-sensation sales team, although it expects to be on track by the end of the second quarter.
Operating expenses decreased slightly, but the company still reported a net loss of $3.8 million for the quarter.
The BLA process limits Axogen Inc (AXGN)'s ability to make significant process improvements until after approval, affecting potential gross margin improvements.
There is a risk of disruption in hospital access or product availability due to potential PNT committee approvals required for the biologics designation.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AXGN.OQ - AxoGen Inc
Q1 2025 AxoGen Inc Earnings Call
May 08, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning everyone.

Joining me on today's call is Michael Dale, Agen's Chief Executive Officer and director, Nir Nawor, Chief Financial Officer, and Jens Kemp, Chief Marketing Officer. Michael will discuss first quarter of 2025 financial results and corporate highlights.

Near will then provide an analysis of our financial performance and guidance and discuss our outlook for the year, followed by a question and answer session. Today's call is being broadcasted live via webcast, which is available on the investors section of Axygen's website.

Following the end of the live call, a replay will be available in the investor section of the company's website at www.t. Exogeninc.com.

Before we get started, I'd like to

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.